Get the Stockscreener App
87.17
0.42%
-0.37
Pre-market:
87.23
0.06
+0.07%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $87.17, with a volume of 17.12M.
It is down -0.42% in the last 24 hours and down -15.26% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$87.54
Open:
$87.31
24h Volume:
17.12M
Relative Volume:
1.45
Market Cap:
$151.83B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
24.28
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
-7.13%
1M Performance:
-15.26%
6M Performance:
-30.01%
1Y Performance:
-34.26%
1-Day Range:
$86.16
$87.83
1-Week Range:
$86.16
$93.72
52-Week Range:
$86.16
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott stock is trading at 52-week lows but insiders are gobbling up shares of this blue-chip dividend payer - MSN
Court upholds $495 million verdict against Abbott Laboratories in case over preterm infant formula - Chicago Tribune
Missouri appeals court upholds $495M ruling against Abbott in baby formula case - Seeking Alpha
Abbott stock tumbles below key moving averages as sellers dominate momentum: weekly outlook - Traders Union
Bioabsorbable Stents Industry Projected to Grow at 10.2% CAGR, - openPR.com
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Selling pressure pushes Abbott Laboratories stock lower in today's trading - Traders Union
Abbott gets FDA nod, CE mark for AI-enabled imaging device - MedTech Dive
Abbott Laboratories: performance and outlook - Business Recorder
This Dividend King's Yield Hasn't Been This High in a Decade. Is It a Buy? - The Globe and Mail
This Dividend King's Yield Hasn't Been This High in a Decade. Is It a Buy? - The Motley Fool
Horizon Investments LLC Sells 48,862 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Offers Growth Potential and High Dividends - HarianBasis.co
Abbott Laboratories $ABT Stock Holdings Lowered by CENTRAL TRUST Co - MarketBeat
ABT: Abbott Laboratories Director Acquires 10,000 Shares Amid De - GuruFocus
AGNC, Lam, Abbott, BlackRock, Schlumberger: Insider Shockwave - TipRanks
Strs Ohio Decreases Stake in Abbott Laboratories $ABT - MarketBeat
PFA Pension Forsikringsaktieselskab Makes New Investment in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Q1 2026 Earnings: $2B CGM Quarter, 65% Upside Priced In - TIKR.com
1 Magnificent Dividend Stock Down 30% to Buy and Hold Forever - The Motley Fool
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
AI Models Split on Abbott Laboratories (ABT) as Fundamentals Clash With Technical and Valuation Concerns - TipRanks
Abbott Laboratories (ABT) Receives FDA Clearance and CE Mark for Next-Generation Ultreon™ 3.0 Software - Yahoo Finance
Abbott–Exact Sciences, BioMarin–Amicus among deals cleared in Japan in Q1 - MLex
ABT Stock Price, Quote & Chart | ABBOTT LABORATORIES (NYSE:ABT) - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
How Investors Are Reacting To Abbott (ABT) Gaining FDA, CE Clearance For AI-Guided Ultreon 3.0 - Yahoo Finance
Abbott Laboratories stock hits 52-week low at $90.72 - Investing.com
Abbott Laboratories stock hits 52-week low at $90.72 By Investing.com - Investing.com Australia
FDA Reports Baby Formula Safety, Highlights Abbott (ABT) Among C - GuruFocus
Abbott Laboratories (FRA:ABL0) Stock Price, Trades & News - GuruFocus
Abbott Receives FDA Clearance, CE Mark for Ultreon 3.0 AI Imaging Platform - AIM Media House
ABT SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Abbott Laboratories (ABT) Stock Price, Trades & News - GuruFocus
FDA search for baby formula contamination finds little - Crain's Chicago Business
Abbott Laboratories (ABT) EVP reports 5,314-share trust move - Stock Titan
Vanguard reports 130.7M shares in Abbott Laboratories (ABT) — 7.5% stake - Stock Titan
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
Ultreon 3.0 regulatory milestone sees Abbott Laboratories stock down 2.64% amid oversold conditions - Traders Union
[10-Q] ABBOTT LABORATORIES Quarterly Earnings Report - Stock Titan
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Lawsuit Claims Abbott, Boston Scientific SCS Pre-Market Approval Supplements Caused Permanent Injuries - AboutLawsuits.com
Fund Update: 1,400,797 ABBOTT LABORATORIES (ABT) shares added to FLOSSBACH VON STORCH SE portfolio - Quiver Quantitative
Abbott Laboratories Stock: Why Analysts Rate a Buy in 2026 - TIKR.com
Abbott’s Ultreon 3.0 AI Imaging Clearance And What It Means For Valuation - simplywall.st
Abbott’s FDA-Cleared Ultreon 3.0 Redefines Imaging in Coronary Interventions - The Indian Practitioner
Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott By Investing.com - Investing.com Canada
Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott - Investing.com
Here’s Why Polen Focus Growth Exited Abbott Laboratories (ABT) in Q1 - Yahoo Finance
Major Insider Move Signals Growing Confidence at Abbott Laboratories - TipRanks
Abbott (NYSE: ABT) awards director 2,286 restricted stock units - Stock Titan
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.50%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):